Search Results - "Terminello, Bianca"

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies by Clements, John David, Zhu, Min, Kuchimanchi, Mita, Terminello, Bianca, Doshi, Sameer

“…Background and objectives Blinatumomab (BLINCYTO ® ) is a novel bispecific T cell engager (BiTE ® ) approved in the USA for the treatment of relapsed or…”
Get full text

Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects by Trivedi, Ashit, Mackowski, Mia, Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Terminello, Bianca, Bhatia, Ajay, Dutta, Sandeep, Lee, Edward

“…Background and Objective Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two…”
Get full text

Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations by Trivedi, Ashit, Hsu, Cheng‐Pang, Jafarinasabian, Pegah, Terminello, Bianca, Zhang, Hanze, Flach, Stephen, Israel, Samuel, Brooks, Ashley, Xue, Hongqi, Darpo, Borje, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Aims Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure. This study aimed to evaluate…”
Get full text

Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator by Trivedi, Ashit, Oberoi, Rajneet K., Mackowski, Mia, Jafarinasabian, Pegah, Zhang, Hanze, Flach, Stephen, Simiens, Mary Ann, Terminello, Bianca, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Omecamtiv mecarbil (OM) is a cardiac myosin activator in clinical development for the treatment of heart failure. The effect of food on the pharmacokinetics…”
Get full text

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects by Trivedi, Ashit, Sohn, Winnie, Jafarinasabian, Pegah, Zhang, Hanze, Terminello, Bianca, Flach, Stephen, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward

“…Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is…”
Get full text